This study is currently recruiting.
Description: A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects with Cerebral Adrenoleukodystrophy
Eligibility & Criteria IRB #: IRB00382750
Principal Investigator: Eric Mallack, MD
Eligible Age Range: 18+ Gender: Male
Diagnosis: Cerebral Adrenoleukodystrophy